In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Five-year results of endovascular treatment of patients with left main coronary arteries bifurcation lesions

Session Poster session 1

Speaker Associate Professor Daniil Maximkin

Congress : ESC Congress 2017

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Coronary Artery Disease (Chronic)
  • Session type : Poster Session
  • FP Number : P898

Authors : D A Maximkin (Moscow,RU), Z Shugushev (Moscow,RU), R Goloshchapov-Aksenov (Moscow,RU), A Chepurnoy (Moscow,RU), A Faibushevich (Moscow,RU)

Authors:
D.A. Maximkin1 , Z. Shugushev1 , R. Goloshchapov-Aksenov1 , A. Chepurnoy2 , A. Faibushevich1 , 1RUDN University - Moscow - Russian Federation , 2Central Clinical Hospital of Russian Railways - Moscow - Russian Federation ,

Citation:
European Heart Journal ( 2017 ) 38 ( Supplement ), 201

Aims: To evaluate long-term results of endovascular treatment in patients with bifurcation left main coronary artery diseases.

Methods and results: 284 patients were enrolled in the study, which randomized into 2 groups: group I (n=132) were included patients with true bifurcation lesions, which implanted Everolimus-eluting stents, and group II (n=152) – were non-bifurcations, which implanted Paclitaxel-eluting stents. The both groups were additionally randomized into 2 subgroups: subgroup IA, IIA (n=66 in each subgroup) - included patients, who underwent 1-stent bifurcation strategy and subgroup IB, IIB (n=76 in each subgroup) - who underwent 2-stent strategy (Culotte and Crush/Mini-Crush). For all patients, who underwent 2 stents in bifurcation, were performing subanalysis, depending on the technique of bifurcation stenting. Inclusion criteria: true and non-bifurcation lesions of left main coronary artery + 1 or 2 vessel diseases (SYNTAX score <32); stenosis of the left main coronary artery, confirmed by FFR<0.8; stable angina classes II-IV (CCS). Primary endpoints: MACE. Secondary endpoints: restenosis and late stent thrombosis according to digital angiography and IVUS.

In group I, who implanted Everolimus-eluting stents, MACE was 5.3%. In group II, who implanted Paclitaxel-eluting stents, frequency of MACE was 7.2% (p=0,003). The ratio of restenosis in bifurcation area, according digitalangiographyin both groups was 6.8 and 9.8% respectively (p=0.0024). Ratio of TLR in both groups amounted 4.5 and 6.5% respectively (p=0.004). IVUS-results in subgroup IA and IIA:the average residual lumen area in the proximal part of LMCA was 7,02+0,03 and 7.55+0.02 mm2 (p>0.05), at the ostia of the LCx - 5,0+0,12 and 5,88+0,01 mm2 (p=0.02), at the ostia of the LAD - 6,13+0,03 and 6.88+0,04 mm2 (p=0.03). The MACE in subgroup IA and IIA was 9.1 and 1.5% respectively (p<0.001). IVUS-results in subgroup IIA and IIB:the average residual lumen area in the proximal part of LMCA was 7,22+0,03 and 7.55+0.02 mm2 (p>0.05), at the ostia of the LCx - 5,0+0,12 and 5,64+0,01 mm2 (p=0.024), at the ostia of the LAD - 6,0+0,03 and 6.84+0,04 mm2 (p=0.027). The MACE in subgroup IB and IIB was 10.5 and 3.9% respectively (p<0.001).142 patients in the study were implanted two stents at the bifurcation. The distribution of patients according to the stenting technique was equivalent, with 70 in each group. The MACE in Culotte and Crush/Mini-Crushgroups was 0 and 5.7% respectively (p<0.001). Defined stent thrombosis were no significant difference in both groups.

Conclusions: Everolimus-eluting stents associated with higher efficacy and safety in bifurcation stenting of left main coronary artery, compared with Paclitaxel-eluting stents. Culotte-technique of LMCA bifurcation stenting shows better long-term results, as compared to Crush/Mini-Crush-technique. Two-stent strategy can be the preferred for endovascular treatment of true left main coronary artery bifurcation lesions.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are